{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:43:57Z","timestamp":1792190637622,"version":"4.4.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004686","name":"Deanship of Scientific Research, King Faisal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Diabetes mellitus (DM) is one of the leading causes of morbidity and mortality worldwide. DM patients with diabetic neuropathy (DN) usually present with distal pain, sensorimotor polyneuropathy, postural hypotension, or erectile dysfunction. They also may present with other nerve pathologies such as inflammatory neuropathies and carpal tunnel syndrome. We conducted a systematic review and meta-analysis to assess the benefits of using sodium\u2013glucose co-transporter-2 inhibitors (SGLT2Is) to manage DN. An extensive systematic literature review was conducted to include all articles published up to 24 February 2022. All clinical studies included patients with DM and reported the outcomes of SGLT2I on diabetes-associated neuropathy. Six studies were identified for meta-analysis, including a total of 5312 diabetic patients. The average age of the included patients ranged from 41 to 74\u00a0years and 34\u201373\u00a0years in the SGLT2I treatment and control groups, respectively. SGLT2I moderately improved the manifestations of diabetic peripheral neuropathy events and nerve conduction velocity. Furthermore, the SGLT2I treatment group had a statistically significant higher mean heart-to-mediastinum ratio (MD 0.41; 95% 0.17, 0.64; <jats:italic>p<\/jats:italic> = 0.0006). However, the mean heart rates (MD \u22124.51; 95% \u221210.05, 1.04; <jats:italic>p<\/jats:italic> = 0.11) and wash out rates (MD 2.13; 95% \u22128.48, 12.75; <jats:italic>p<\/jats:italic> = 0.69) were not significantly different between the two groups. SGLT2Is could therefore be considered neuroprotective in patients with DN, possibly by considerably increasing the sensory and motor nerve conduction velocity, improving the clinical manifestations of DPN, and reducing sympathetic nervous system activity.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>http:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>, identifier CRD42022312828<\/jats:p>","DOI":"10.3389\/fphar.2022.926717","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T07:46:04Z","timestamp":1657525564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Mahmoud","family":"Kandeel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"B1","first-page":"2007","volume-title":"Comprehensive Meta-Analysis V2","author":"Borenstein","year":"2005"},{"key":"B2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/B978-0-444-53480-4.00008-4","article-title":"Diabetic Neuropathy and Foot Complications","volume":"126","author":"Boulton","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/ph15030282","article-title":"Drug Discovery of New Anti-inflammatory Compounds by Targeting Cyclooxygenases","volume":"15","author":"Burayk","year":"2022","journal-title":"Pharm. (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s13300-021-01004-2","article-title":"Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies","volume":"12","author":"Caparrotta","year":"2021","journal-title":"Diabetes Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative Safety of the Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors: a Systematic Review and Meta-Analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s00125-019-4959-1","article-title":"New Insights into the Mechanisms of Diabetic Complications: Role of Lipids and Lipid Metabolism","volume":"62","author":"Eid","year":"2019","journal-title":"Diabetologia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1762164","DOI":"10.1155\/2020\/1762164","article-title":"SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: a Review","volume":"2020","author":"El Mouhayyar","year":"2020","journal-title":"Int. J. Endocrinol."},{"key":"B6","first-page":"S38","article-title":"Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series","volume":"5","author":"Green","year":"2008","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Exp Pathol Pharmakol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the Mean and Variance from the Median, Range, and the Size of a Sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"B13","volume-title":"Diabetes Facts & Figures, the IDF Diabetes Atlas Ninth Edition 2019","author":"Idf","year":"2019"},{"key":"B14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","article-title":"The Effect of Empagliflozin on Muscle Sympathetic Nerve Activity in Patients with Type II Diabetes Mellitus","volume":"11","author":"Jordan","year":"2017","journal-title":"J. Am. Soc. Hypertens."},{"key":"B15","doi-asserted-by":"publisher","first-page":"105633","DOI":"10.1016\/j.compbiomed.2022.105633","article-title":"Omicron Variant Receptor-Binding Domain Phylogenetics and Molecular Dynamics","volume":"146","author":"Kandeel","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6422208","DOI":"10.1155\/2022\/6422208","article-title":"The Application of Natural Camel Milk Products to Treat Autism-Spectrum Disorders: Risk Assessment and Meta-Analysis of Randomized Clinical Trials","volume":"2022","author":"Kandeel","year":"2022","journal-title":"Bioinorg. Chem. Appl."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e12929","DOI":"10.7717\/peerj.12929","article-title":"Antiviral Drug Discovery by Targeting the SARS-CoV-2 Polyprotein Processing by Inhibition of the Main Protease","volume":"10","author":"Kandeel","year":"2022","journal-title":"PeerJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2991\/dsahmj.k.210921.001","article-title":"Virtual Screening and Inhibition of Middle East Respiratory Syndrome Coronavirus Replication by Targeting Papain-like Protease","volume":"3","author":"Kandeel","year":"2021","journal-title":"Dsahmj"},{"key":"B19","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/jphp.13241","article-title":"Treatment of Diabetic Peripheral Neuropathy: a Review","volume":"72","author":"Khdour","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.18388\/pb.2019_287","article-title":"Cardiovascular Autonomic Neuropathy in the Course of Diabetes - the Review of Actual Knowledge","volume":"65","author":"Kie\u0107-Wilk","year":"2019","journal-title":"Postepy Biochem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4062\/biomolther.2022.037","article-title":"Abiraterone Acetate Attenuates SARS-CoV-2 Replication by Interfering with the Structural Nucleocapsid Protein","volume":"1","author":"Kim","year":"2022","journal-title":"Biomol. Ther. Seoul."},{"key":"B22","doi-asserted-by":"publisher","first-page":"101331","DOI":"10.1016\/j.diabet.2022.101331","article-title":"The Impact of Canagliflozin on the Risk of Neuropathy Events: a Post-hoc Exploratory Analysis of the CREDENCE Trial","volume":"48","author":"Liao","year":"2022","journal-title":"Diabetes & Metabolism"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 Inhibitors in Type 2 Diabetes: Weighing the Risks and Benefits","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e20208","DOI":"10.7759\/cureus.20208","article-title":"Effectiveness of Empagliflozin with Vitamin D Supplementation in Peripheral Neuropathy in Type 2 Diabetic Patients","volume":"13","author":"Mehta","year":"2021","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"B26","volume-title":"National Institute of Health, Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies","author":"National Heart, Lung, and Blood Institute","year":"2014"},{"key":"B27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic Neuropathy: a Position Statement by the American Diabetes Association","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.bbadis.2016.04.017","article-title":"Common Neurodegenerative Pathways in Obesity, Diabetes, and Alzheimer's Disease","volume":"1863","author":"Pugazhenthi","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B29","volume-title":"WebPlotDigitizer (Version 4.2) [Computer Software]","author":"Rohatgi","year":"2018"},{"key":"B30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 Inhibitor Improve Brain Function via Attenuating Mitochondrial Dysfunction, Insulin Resistance, Inflammation, and Apoptosis in HFD-Induced Obese Rats","volume":"333","author":"Sa-Nguanmoo","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-1317377\/v1","volume-title":"SGLT2-inhibitors Modulate the Cardiac Autonomic Neuropathy and Reduce the Vaso-Vagal Syncope Recurrence in Patients with Type 2 Diabetes Mellitus: The SCAN Study","author":"Sardu","year":"2022"},{"key":"B33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of Empagliflozin versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: the EMBODY Trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3389\/fnins.2021.708547","article-title":"Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus","volume":"15","author":"Sim","year":"2021","journal-title":"Front. Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa032782","article-title":"Vascular Risk Factors and Diabetic Neuropathy","volume":"352","author":"Tesfaye","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1007\/s00125-020-05194-5","article-title":"Cardiometabolic Risk Factors as Determinants of Peripheral Nerve Function: the Maastricht Study","volume":"63","author":"van der Velde","year":"2020","journal-title":"Diabetologia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: a Systematic Review and Meta-Analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"B38","first-page":"2211","article-title":"Effect of Dapagliflozin Combined with Mecobalamin on Blood Glucose Concentration and Serum MDA, SOD, and COX-2 in Patients with Type 2 Diabetes Mellitus Complicated with Peripheral Neuropathy","volume":"35","author":"Wang","year":"2019","journal-title":"Acta medica Mediterr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/ph13110379","article-title":"Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer\u2019s Disease and Ischemia-Related Brain Injury","volume":"13","author":"Wici\u0144ski","year":"2020","journal-title":"Pharmaceuticals"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40842-016-0039-3","article-title":"Diabetes and its Drivers: the Largest Epidemic in Human History?","volume":"3","author":"Zimmet","year":"2017","journal-title":"Clin. Diabetes Endocrinol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of Intensive Glucose Control on Microvascular Outcomes in Patients with Type 2 Diabetes: a Meta-Analysis of Individual Participant Data from Randomised Controlled Trials","volume":"5","author":"Zoungas","year":"2017","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.926717\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T07:46:13Z","timestamp":1657525573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.926717\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":40,"alternative-id":["10.3389\/fphar.2022.926717"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.926717","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"article-number":"926717"}}